Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.08), $0.33 better than the analyst estimate of ($1.41). Revenue for the quarter came in at $81.6 million versus the consensus estimate of $81.55 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order